GSK has claimed US approval for Jemperli alongside chemotherapy for previously untreated, primary advanced or recurrent endometrial cancer, becoming the first immunotherapy option for first-line ...

GSK has built the case for first-line use of its PD-1 inhibitor Jemperli in endometrial cancer, with new survival data that could help it expand the label for the drug. The latest readout from the ...

The tolerability and safety profile for Jemperli combined with carboplatin-paclitaxel was consistent with the known safety profiles of the individual agents. Endometrial cancer originates in the ...

Jemperli was approved for similar expanded use in endometrial cancer in the United States in August 2024. The drug is also approved for second-line endometrial cancer and dMMR recurrent or ...

The researchers found biomarkers of macrophage activity and immune activity were associated with resistance and response to Opdivo plus Cabometyx.

ANAB remains risky despite new clinical data and partnerships; past successes haven't been replicated, and management's transparency issues raise concerns.

Regulatory bodies, including the FDA, are accelerating approvals for new therapies, such as the 2024 approval of Jemperli in combination with chemotherapy, marking a significant milestone in treating ...

We are proud Jemperli continues to redefine the treatment landscape for patients," said Hesham Abdullah, GSK's global head of Oncology. Endometrial cancer, the most common gynecologic cancer in ...

GSK PLC on Monday said the European Commission has expanded approval for its drug Jemperli, in combination with chemo ... Subscribe now to see this Premium News article from Alliance News ...